Nabriva Therapeutics (NASDAQ:NBRV) Earns Hold Rating from Analysts at StockNews.com
StockNews.com assumed coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research report released on Saturday. The firm issued a hold rating on the biotechnology company’s stock. Nabriva Therapeutics Price Performance Nabriva Therapeutics has a one year low of $1.22 and a one year high of $8.45. The company has a market […]
More Stories
QuickLogic (NASDAQ:QUIK) Posts Earnings Results, Misses Expectations By $0.01 EPS
QuickLogic (NASDAQ:QUIK – Get Free Report) issued its quarterly earnings data on Monday. The semiconductor company reported ($0.06) earnings per...
Braemar Hotels & Resorts (NYSE:BHR) Announces Quarterly Earnings Results, Beats Expectations By $0.02 EPS
Braemar Hotels & Resorts (NYSE:BHR – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.02)...
iShares iBonds Dec 2054 Term Treasury ETF (NASDAQ:IBGK) Short Interest Up 275.0% in October
iShares iBonds Dec 2054 Term Treasury ETF (NASDAQ:IBGK – Get Free Report) was the recipient of a large increase in...
Forte Biosciences, Inc. (NASDAQ:FBRX) Short Interest Update
Forte Biosciences, Inc. (NASDAQ:FBRX – Get Free Report) was the target of a large decrease in short interest in October....
Haoxi Health Technology Limited (NASDAQ:HAO) Short Interest Up 278.4% in October
Haoxi Health Technology Limited (NASDAQ:HAO – Get Free Report) was the recipient of a significant growth in short interest during...
iShares JPX-Nikkei 400 ETF (NYSEARCA:JPXN) Stock Price Down 1.7% – Here’s Why
iShares JPX-Nikkei 400 ETF (NYSEARCA:JPXN – Get Free Report)’s stock price dropped 1.7% on Tuesday . The company traded as...